Viking Therapeutics be acquired before 2027 priced at 9% on Polymarket

Polymarket’s contract on whether Viking Therapeutics will be acquired before 2027 was priced at 9% in the Oct 18, 2026 · 2:39 AM ET update. The reading was down 3 probability points from 12%, with $1.7M traded, according to the supplied market summary.

The decline puts the market-implied probability further below its earlier level. It reflects a change in traders’ pricing, rather than confirmation of any change in acquisition discussions.

What the data establishes

According to predictionbubbles.net, its movers tracker measures probability-point changes over 24 hours using prices from Polymarket and Kalshi, with updates every 15 minutes. The supplied page lists a venue-data snapshot of 18 Oct 2026, 07:18 UTC.

The source material does not identify a company announcement, potential buyer or other development explaining Viking Therapeutics’ repricing. Nor does the supplied summary specify the period covered by the $1.7M traded figure, limiting what can be inferred about activity during the decline.

What it means for prediction markets

• The change is 3 probability points: the contract moved from 12% to 9%, not down 3% in relative terms.
• Volume and liquidity are different measures: $1.7M traded provides activity context but does not establish how much buying or selling would move the current price.
• The deadline defines the question: the contract concerns an acquisition before 2027, not the likelihood of an eventual acquisition.
• The catalyst remains unspecified: the supplied material supports a repricing story, not a conclusion about the status of any deal.